ImmuPharma plc · LSE:IMM

ImmuPharma — Investor Presentation (January 2022)

22 slides from ImmuPharma's investor presentation, January 2022

  1. Slide 1: ImmuPharma

    Ww ImmuPharma BioPharma | Creation | Evolution

  2. Slide 2: BioPharma | Creation | Evolution

    BioPharma | Creation | Evolution

  3. Slide 3: Disclaimer

    Disclaimer This presentation contains certain statements and may be forward- foregoing, no assurance is given as to when ImmuPharma’s products will be engaged in only with such persons. Persons who fall outside looking statements that are subject to a variety of risks and will be launched or whether

  4. Slide 4: Why Invest in ImmuPharma PLC?

    Why Invest in ImmuPharma PLC? § A rich portfolio with 2 highly attractive late-stage clinical indications § Significant intrinsic value in all target product profiles in the portfolio § Highly undervalued on a peer-comparison & DCF basis § Previously only a one-product company (lupus) § Now lupus re

  5. Slide 5: ImmuPharma PLC share price is well below a rational valuation

    ImmuPharma PLC share price is well below a rational valuation Lupuzor phase 3 trial 200p design for lupus was flawed. Study failed 180p 160p 140p 120p 100p FDA approve trial but require a Phase 1 PK study prior to starting Phase 3. 80p New P140 synthesis and cheaper manufacturing Analysis of lupus t

  6. Slide 6: ImmuPharma PLC is headquartered in London & research in Bordeaux

    ImmuPharma PLC is headquartered in London & research in Bordeaux. § Listed on UK AIM (LSE:IMM) § Major board and management change in August 2021 • Pipeline of innovative peptide-based therapies • Portfolio in two core therapy areas: Autoimmunity/Inflammation and Anti-infection • Lupuzor® (P140) for

  7. Slide 7: New Team

    NEW TEAM Tim McCarthy FCCA, MBA Tim Franklin, PhD, MBA Chief Executive Officer Chief Operating Officer Ewa Flynn FCCA Dr Sanjeev Pandya MBA Lisa Baderoon Chief Financial Officer & Company Senior Non-Executive Director Non-Executive Director Secretary and Head of Investor Relations 7

  8. Slide 8: Team experience

    ce) Team experience ImmuPharma Y 0) S Pfizer incanthera DP csi reckitt @Buchanan Bear Company gy TEXACO FY axcciiieary x €) Dresdner Kleinwort 52 Abasebio e Cambridge Antibody Technology igs Oi YS » \/ 4 SULN. LEHMAN BROTHERS ALIZYME.COM SmithKline Beecham

  9. Slide 9: Therapy Focus

    Therapy Focus Autoimmunity & inflammation Anti-infection 9

  10. Slide 10: Lupuzor P140, BioAMB, BioCIN core assets

    4 core assets, 2 late stage clinical Lupuzor ® P140 BioAMB BioCIN Autoimmunity Inflammation Anti-infection Anti-infection Lupus CIDP Severe Fungal Severe Bacterial Infection infection Status: Status: New optimized phase III Phase II/III (pivotal) Status: Status: Late pre-clinical Early pre-clinical

  11. Slide 11: Portfolio & pipeline

    Portfolio & pipeline 11

  12. Slide 12: Portfolio & pipeline

    Portfolio & pipeline An innovative peptide portfolio FDA Preclinical Phase I Phase II Phase III ImmuPharma PLC is a biopharmaceutical company Approval developing novel peptide therapeutics ImmuPharma’s pipeline is focused on 2 core therapeutic LupuzorTM areas; autoimmunity/inflammation and anti-infe

  13. Slide 13: Autoimmunity & Inflammation

    Autoimmunity & Inflammation The P140 franchise LUPUZORTM for Lupus P140 for CIDP 13

  14. Slide 14: Lupuzor for Lupus

    LUPUZORTM for Lupus About Lupus LupuzorTM, (forigerimod or P140) is moving into phase III in 2022 Targets systemic lupus erythematosus (SLE), an autoimmune Systemic lupus erythematous (sle) is a chronic, life- disease for which there is currently no cure. Two approved threatening autoimmune, inflamm

  15. Slide 15: Partnerships & Alliances

    Partnerships & Alliances • ImmuPharma and US Avion Pharmaceuticals signed exclusive license and development agreement for LupuzorTM to fund a new ‘optimized’ international Phase III trial. • LupuzorTM Phase III funded up to $25m • Milestones up to $70m & tiered double-digit royalties up to 17% • Avi

  16. Slide 16: P140 for CIDP

    1; ImmuPharma BioPharma | Creation | Evolution —-l4 for CIDP

  17. Slide 17: P140 for CIDP

    P140 for CIDP P140 (forigerimod) shows compelling *pre-clinical About CIDP data in Chronic Inflammatory Demyelinating Polyneuropathy (“CIDP”) CIDP is neurological autoimmune disease targeting the nerves. Symptoms include: fatigue, areas of numbness, slow reflexes, weakness in arms and legs. It is ch

  18. Slide 18: BioAMB

    BioAMB for systemic fungal infections 18

  19. Slide 19: BioAMB for systemic fungal infections

    BioAMB for systemic fungal infections BioAMB is a novel biomodified peptide- based drug that offers a potential About Anti-Infectives improvement on Amphotericin-B (“Amp-B”). Anti-infectives : Increased antibiotic and anti-fungal resistance is Currently marketed AMB-B formulations one of the biggest

  20. Slide 20: BioCIN

    BioCIN for severe bacterial infections 20

  21. Slide 21: BioCIN for severe bacterial infections

    BioCIN for severe bacterial infections BioCIN is a novel biomodified peptide-based drug that offers a potential improvement on About Anti-Infectives Vancomycin Anti-infectives : Increased antibiotic and anti-fungal resistance is Vancomycin, a generic drug, is a last resort one of the biggest threats

  22. Slide 22: Value Accretive News Flow 2022

    Value Accretive News Flow 2022 § P140 PK study completion Q1 2022 § Lupuzor Phase 3 lupus study commencement from Q2 2022 § FDA approval for CIDP study and orphan drug designation 1st half 2022 § P140 Phase 2/3 adaptive pivotal commencement in CIDP from Q2 2022 § BioAMB efficacy and safety data vers

ImmuPharma — Investor Presentation (January 2022) on 6ix